Myocardial viability assessment by PET: 82Rb defect washout does not predict the results of metabolic-perfusion mismatch

Journal of Nuclear Medicine

Volumn 46, Issue 10, 2005, Pages 1602-1609

  Stankewicz, Mark A ^a   Mansour, Craig S ^a   Eisner, Robert L ^b   Churchwell, Keith B ^a   Williams, Byron R ^a   Sigman, Steven R ^a   Streeter, James ^a   Patterson, Randolph E ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

82Rb; Coronary artery disease; Myocardial perfusion imaging; Myocardial viability; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RUBIDIUM 82; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; RUBIDIUM;

ADULT; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE SEVERITY; FEMALE; HEART LEFT VENTRICLE FAILURE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MISMATCH NEGATIVITY; PATIENT REFERRAL; PERFUSION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT INDICATION; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; REPRODUCIBILITY; RETROSPECTIVE STUDY; SCINTISCANNING; STUNNED HEART MUSCLE;

FEMALE; HEART VENTRICLES; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MYOCARDIAL STUNNING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RUBIDIUM RADIOISOTOPES; SENSITIVITY AND SPECIFICITY; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33644691629     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. 18F-labeled fluorodeoxyglucose, and N-13 ammonia. Circulation. 1983;67:766-778.
2. Camici P, Araujo L, Spinks T, Lammertsma AA, Jones T, Maseri A. Myocardial glucose utilization in ischemic heart disease: preliminary results with F18-fluorodeoxyglucose and positron emission tomography. Eur Heart J. 1986;7:19-23.
3. Brunken RC, Schwaiger M, Grover-McKay M, et al. Positron emission tomography detects tissue metabolic activity in myocardial segments with persistent thallium perfusion defects. J Am Coll Cardiol. 1987;10:557-567.
4. Schwaiger M, Brunken RC, Krivokapich J, et al. Beneficial effect of residual anterograde flow on tissue viability as assessed by positron emission tomography in patients with myocardial infarction. Eur Heart J. 1987;8:981-988.
5. Gropler RJ, Siegel BA, Sampathkumaran K, et al. Dependence of recovery of contractile function on maintenance of oxidative metabolism after myocardial infarction. J Am Coll Cardiol. 1992;19:989-997.
6. Klocke FJ, Baird MG, Bateman TM, et al., eds. ACC/AHA/ASNC Guidelines for the Clinical Use of Cardiac Radionucleotide Imaging. Available at: http://www. acc.org/clinical/guidelines/radio/nri_fulltext.pdf. Accessed September 22, 2004.
7. Tillisch J, Brinken R, Marshall R, et al. Reversibility of cardiac wall motion abnormalities predicted by positron tomography. N Engl J Med. 1996;314:884-888.
8. Bonow RO, Dilsizian V, Cuocolo A, et al. Identification of viable myocardium in patients with chronic coronary artery disease and left ventricular dysfunction and PET imaging with 18-F-florodeoxyglucose. Circulation. 1991;83:26-37.
9. Marwick TH, MacIntyre WJ, Lafont A, et al. Metabolic responses of hibernating and infarcted myocardium to revascularization: a follow-up study of regional perfusion, function, and metabolism. Circulation. 1992;85:1347-1353.
10. Eitzman D, Al-Aouar ZR, Kanter HL, et al. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol. 1992;20:559-565.
11. Tamaki N, Kawamoto M, Takahashi N, et al. Prognostic value of an increase in fluorine-18 deoxyglucose uptake in patients with myocardial infarction: comparison with stress thallium imaging. J Am Coll Cardiol. 1993;22:1621-1627.
12. DiCarli MF, Davidson M, Little R, et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol. 1994;73:527-533.
13. Goldstein R, Mullani N, Wong W, et al. Positron imaging of myocardial infarction with rubidium-82. J Nucl Med. 1986;27:1824-1829.
14. Gould K, Goldstein R, Mullani N, et al. Noninvasive assessment of coronary stenoses by myocardial perfusion imaging during pharmacologic coronary vasodilation. VIII. Clinical feasibility of positron cardiac imaging without a cyclotron using generator-produced rubidium-82. J Am Cardiol. 1986;7:775-789.
15. Gould KL. Identifying and measuring severity of coronary artery stenosis: quantitative coronary arteriography and positron emission tomography. Circulation. 1988;78:237-245.
16. Gould K, Goldstein R, Mullani N, et al. Clinical feasibility, sensitivity and specificity of positron cardiac imaging without a cyclotron using generator produced Rb-82 for the diagnosis of coronary artery disease [abstract]. J Nucl Med. 1986;27(suppl):P976.
17. Demer L, Gould K, Goldstein R, et al. Assessment of coronary artery disease severity by positron emission tomography: comparison with quantitative arteriography in 193 patients. Circulation. 1989;79:825-835.
18. Go RT, Marwick TH, MacIntyre WJ, et al. A prospective comparison of rubidium-82 PET and thallium-201 SPECT myocardial perfusion imaging utilizing a single dipyridamole stress in the diagnosis of coronary artery disease. J Nucl Med. 990;31:1899-1905.
19. Marwick TH, MacIntyre WJ, Salcedo EE, et al. Identification of ischemic and hibernating myocardium: feasibility of post-exercise E-18 deoxyglucose positron emission tomography. Cathet Cardiovasc Diagn. 1991;22:100-106.
20. Stewart RE, Schwaiger M, Molina E, et al. Comparison of rubidium-82 positron emission tomography and thallium-201 SPECT imaging for detection of coronary artery disease. Am J Cardiol. 1991;67:1303-1310.
21. Goldstein R. Kinetics of rubidium-82 after coronary occlusion and reperfusion: assessment of patency and viability in open-chested dogs. J Clin Invest. 1985; 75:1131-1137.
22. Goldstein RA. Rubidium-82 kinetics after coronary occlusion: temporal relation of net myocardial accumulation and viability in open-chested dogs. J Nucl Med. 1986;27:1456-1461.
23. Gould KL, Yoshida K, Hess MJ, et al. Myocardial metabolism of fluorodeoxyglucose compared to cell membrane integrity for the potassium analogue rubidium-82 for assessing infarct size in man by PET. J Nucl Med. 1991;32:1-9.
24. vom Dahl J, Muzik O, Wolfe ER, et al. Myocardial rubidium-82 tissue kinetics assessed by dynamic positron emission tomography as a marker of myocardial cell membrane integrity and viability. Circulation. 1996;93:238-244.
25. Bacharach SL, Bax JJ, Case J, et al. PET myocardial glucose metabolism and perfusion imaging. Part 1. Guidelines for data acquisition and patient preparation. J Nucl Cardiol. 2003;10:543-556.
26. Patterson RE, Horowitz SF, Eisner RL. Comparison of modalities to diagnose coronary artery disease. Semin Nucl Med. 1994;24:286-310.
27. Go RT, Macintyre WJ, Saha GB, et al. Hibernating myocardium versus scar: severity of irreversible decreased myocardial perfusion in prediction of tissue viability. Radiology. 1995;194:151-155.
28. Sorensen JA, Phelps ME. Physics in Nuclear Medicine. Philadelphia, PA: WB Saunders; 1987:406-408.
29. Basingthwaite JB. Flow estimation from tracer washout. Prog Cardiovasc Dis. 1977;20:83-107.
30. Mullani NA, Goldstein RA, Gould KL, et al. Myocardial perfusion with rubidium-82: measurement of extraction fraction and flow with external detectors. J Nucl Med. 1983;24:898-906.